Ceftobiprole – a case study

Bibliography

• CHAMBERS HF: The changing epidemiology of Staphylococcus aureus? Emerging infectious diseases (2001) 7:178-182.
   PubMed Web of Science ®Google Scholar
• UTSUI Y, TAJIMA M, SEKIGUCHI Y, SUZUKI E, YOKOTA T: Role of an altered penicillin-binding protein (PBP) and membrane-bound penicillinase in cephem-resistant Staphylococcus aureus. In: Proceedings for the 13th International Congress of Chemotherapy. Spitzy KH, Karrer K (Eds), Verlag H Egermann, Vienna, Austria (1983):2 88/7-88/10.
   Google Scholar
• HARTMAN BJ, TOMASZ A: Low-affinity penicillin-binding protein associated with β-lactam resistance in Staphylococcus aureus. J. Bacteriol. (1984) 158:513-516.
   PubMed Web of Science ®Google Scholar
• FONTANA R, ROSSI L, RONG YC, TONIN E: Penicillin-binding proteins and resistance to β-lactam antibiotics in Staphylococcus aureus. Chemioterapia (1985) 4:53-55.
   PubMedGoogle Scholar
• MURAKAMI K, NOMURA K, DOI M, YOSHIDA T: Production of low-affinity penicillin-binding protein by low- and high-resistance groups of methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. (1987) 31:1307-1311.
   PubMed Web of Science ®Google Scholar
• RYFFEL C, TESCH W, BIRCH-MACHIN I et al.: Sequence comparison of mecA genes isolated from methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis. Gene (1990) 94:137-138.
   PubMed Web of Science ®Google Scholar
• LIM D, STRYNADKA NC: Structural basis for the β-lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus. Nat. Struct. Biol. (2002) 9:870-876.
   PubMedGoogle Scholar
• SAUVAGE E, KERFF F, FONZE E et al.: The 2.4 Å crystal structure of the penicillin-resistant penicillin-binding protein PBP5fm from Enterococcus faecium in complex with benzylpenicillin. Cell. Mol. Life Sci. (2002) 59:1223-1232.
   PubMed Web of Science ®Google Scholar
• PARES S, MOUZ N, PETILLOT Y, HAKENBECK R, DIDEBERG O: X-ray structure of Streptococcus pneumoniae PBP2x, a primary penicillin target enzyme. Nat. Struct. Biol. (1996) 3:284-289.
   PubMedGoogle Scholar
• GOFFIN C, GHUYSEN J-M: Biochemistry and comparative genomics of SxxK superfamily acyltransferases offer a clue to the mycobacterial paradox: presence of penicillin-susceptible target proteins versus lack of efficiency of penicillin as therapeutic agent. Microbiol. Mol. Biol. Rev. (2002) 66:702-738.
   PubMed Web of Science ®Google Scholar
• GRAVES-WOODWARD K, PRATT RF: Reaction of soluble penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus with β-lactams and acyclic substrates: kinetics in homogeneous solution. Biochem. J. (1998) 332:755-761.
   PubMed Web of Science ®Google Scholar
• CHITTOCK RS, WARD S, WILKINSON A-S et al.: Hydrogen bonding and protein perturbation in β-lactam acyl-enzymes of Streptococcus pneumoniae penicillin-binding protein PBP2x. Biochem. J. (1999) 338:153-159.
   PubMed Web of Science ®Google Scholar
• PAGE MG: The reaction of cephalosporins with penicillin-binding protein from Escherichia coli. Biochim. Biophys. Acta (1994) 1205:199-206.
   PubMed Web of Science ®Google Scholar
• JAMIN M, DAMBLON C, MILLIER S, HAKENBECK R, FRÈRE J-M: Penicillin-binding protein 2x of Streptococcus pneumoniae: enzymic activities and interactions with β-lactams. Biochem. J. (1993) 292:735-741.
   PubMed Web of Science ®Google Scholar
• ROYCHOUDHURY S, KAISER RE, BREMS DN, YEH W-K: Specific interaction between β-lactams and soluble penicillin-binding protein 2a from methicillin-resistant Staphylococcus aureus: development of a chromogenic assay. Antimicrob. Agents Chemother. (1996) 40:2075-2079.
   PubMed Web of Science ®Google Scholar
• PAGE M, BUR D, HEBEISEN P et al.: Inhibition of the penicillin-binding proteins of methicillin-resistant Staphylococcus aureus by pyrrolidinone-3-ylidenemethyl cephems. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (1998):238 Poster F-22.
   Google Scholar
• LU W-P, SUN Y, BAUER MD, PAULE S, KOENIGS PM, KRAFT WG: Penicillin-binding protein 2a from methicillin-resistant Staphylococcus aureus: kinetic characterization of its interactions with β-lactams using electrospray mass spectrometry. Biochemistry (1999) 38:6537-6546.
   PubMed Web of Science ®Google Scholar
• FUDA C, SUVOROV M, VAKULENKO SB, MOBASHERY S: The basis for resistance to β-lactam antibiotics by penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus. J. Biol. Chem. (2004) 279:40802-40806.
   PubMed Web of Science ®Google Scholar
• YOKOTA T, YOSHIDA R, UTSUI Y, TAJIMA M: Cefmetazole: a broad spectrum cephem antibiotic effective on methicillin- and cephem-resistant Staphylococcus aureus. Drugs Exp. Clin. Res. (1985) 11:29-38.
   PubMedGoogle Scholar
• SUNGAWA M, YAMAGA H, SHINAGAWA H, HOUCHIGAI H, SUMITA Y: Synthesis and biological properties of a new series of anti-MRSA β-lactams;2-(thiazol-2′-ylthio)carbapenems. Bioorganic Med. Chem. Letts (1994) 4:2793-2798.
   Web of Science ®Google Scholar
• WADDELL ST, RATCLIFFE RW, SZUMILOSKI SP et al.: Benzo-thiazolylthio carbapenems: potent anti-MRSA agents. Bioorganic Med. Chem. Lett. (1995) 5:1427-1432.
   Web of Science ®Google Scholar
• ARNOULD JC, ILLINGWORTH RN, NICHOLS WW, WILSON RG: Synthesis and antibacterial activity of lipophilic carbapenems with anti-MRSA activity. Bioorganic Med. Chem. Lett. (1996) 6:2449-2454.
   Web of Science ®Google Scholar
• OHTAKE N, IMAMURA H, KIYONGA H et al.: Novel dithiocarbamate carbapenems with anti-MRSA activity. Bioorganic Med. Chem. Lett. (1997) 7:1617-1622.
   Web of Science ®Google Scholar
• OHTAKE N, IMAMURA H, JONA H et al.: Novel dithiocarbamate carbapenems with anti-MRSA activity. Bioorganic Med. Chem. (1998) 6:1089-1101.
   PubMed Web of Science ®Google Scholar
• SHINAGAWA H, YAMAGA H, HOUCHIGAI H, SUMITA Y, SUNAGAWA M: Synthesis and biological properties of a new series of anti-MRSA β-lactams; 2-(thiazol-2-ylthio)carbapenems. Bioorganic Med. Chem. (1997) 5:601-621.
   PubMed Web of Science ®Google Scholar
• YASUDA N, HUFFMAN MA, HO GJ et al.: Practical synthesis of anti-methicillin-resistant Staphylococcus aureus (MRSA) carbapenem L-742,728. J. Org. Chem. (1998) 63:5438-5446.
   Web of Science ®Google Scholar
• RATCLIFFE RW, WILKENING RR, WILDONGER KJ et al.: Synthesis and properties of 2-(naphthosultamyl)methyl carbapenems with potent anti-MRSA activity: discovery of L-786,392. Bioorganic Med. Chem. Lett. (1999) 9:679-684.
   PubMed Web of Science ®Google Scholar
• LAUB JB, GREENLEE ML, DININNO F, HUBER JL, SUNDELOF JG: The synthesis and anti-MRSA activity of amidinium-substituted 2-dibenzofuranylcarbapenems. Bioorganic Med. Chem. Lett. (1999) 9:2973-2976.
   PubMed Web of Science ®Google Scholar
• NAGANO R, SHIBATA K, ADACHI Y, IMAMURA H, HASHIZUME T, MORISHIMA H: In vitro activities of novel trans-3,5-disubstituted pyrrolidinythio-1β-methylcarbapenems with potent activities against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. (2000) 44:489-495.
   PubMed Web of Science ®Google Scholar
• IMAMURA H, OHTAKE N, JONA H et al.: Dicationic dithiocarbamate carbapenems with anti-MRSA activity. Bioorganic Med. Chem. (2001) 9:1571-1578.
   PubMed Web of Science ®Google Scholar
• SUNAGAWA M, ITOH M, KUBOTA K et al.: New anti-MRSA and anti-VRE carbapenems; synthesis and structure-activity relationships of 1-β-methyl-2-(thiazol-2-ylthio)carbapenems. J. Antibiotics (2002) 55:722-757.
   PubMed Web of Science ®Google Scholar
• OH CH, LEE SC, CHO JH: Synthesis and biological activity of 1β-methyl-2-[5-(2-N-substituted aminoethylcarbamoyl)pyrrolidin-3-ylthio]carbapenem derivatives. Eur. J. Med. Chem. (2003) 38:841-850.
   PubMed Web of Science ®Google Scholar
• KURAZONO M, IDA T, YAMADA K et al.: In vitro activities of ME1036 (CP-5609), a novel parenteral carbapenem, against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. (2004) 48:2831-2837.
   PubMed Web of Science ®Google Scholar
• KOGA T, ABE T, INOUE H et al.: In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem. Antimicrob. Agents Chemother. (2005) 49:3239-3250.
   PubMed Web of Science ®Google Scholar
• KANNO O, KAWAMOTO I: Stereoselective synthesis of novel anti-MRSA tricyclic carbapenems (trinems). Tetrahedron (2000) 56:5639-5648.
   Web of Science ®Google Scholar
• INAMOTO Y, GOTO J, SAKANE K, KAMIMURA T, TAKAYA T: Studies on beta-lactam antibiotics. XIX. Structure-activity relationships of cephalosporins having a thiadiazolylthiomethyl group at the C-3 side chain. J. Antibiotics (1991) 44:507-516.
   PubMed Web of Science ®Google Scholar
• MINE Y, WATANABE Y, SAKAMOTO H et al.: Excellent activity of FK037, a novel parenteral broad-spectrum cephalosporin, against methicillin-resistant staphylococci. J. Antibiotics (1993) 46:99-119.
   PubMed Web of Science ®Google Scholar
• HANAKI H, AKAGI H, MASARU Y, OTANI T, HYODO A, HIRAMATSU K: TOC-39, a novel parenteral broad-spectrum cephalosporin with excellent activity against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. (1995) 39:1120-1126.
   PubMed Web of Science ®Google Scholar
• HANAKI H, AKAGI H, NOMURA S, UNEMI N, HIRAMATSU K: Structure–activity relationships of cephalosporin derivatives against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis. J. Antibiotics (1996) 49:402-404.
   PubMed Web of Science ®Google Scholar
• HEINZE-KRAUSS I, ANGEHRN P, GUERRY P et al.: Synthesis and structure-activity relationship of (lactamyl)vinylcephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci. J. Med. Chem. (1996) 39:1864-1871.
   PubMed Web of Science ®Google Scholar
• NOMURA S, HANAKI H, UNEMI N: In vitro antibacterial activity of TOC-50, a new parenteral cephalosporin against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis. Chemotherapy (1996) 42:253-258.
   PubMed Web of Science ®Google Scholar
• HECKER SJ, CHO IS, GLINKA TW et al.: Discovery of MC-02,331, a new cephalosporin exhibiting potent activity against methicillin – resistant Staphylococcus aureus. J. Antibiotics (1998) 51:722-734.
   PubMed Web of Science ®Google Scholar
• KISHI K, OHKI H, OKUDA S et al.: Synthesis and biological properties of a novel cephalosporin FR-86521 having potent activity against methicillin-resistant Staphylococcus aureus (MRSA). J. Antibiotics (1999) 52:1152-1155.
   PubMed Web of Science ®Google Scholar
• VOUILLAMOZ J, ENTENZA JM, HOHL P, MOREILLON P: LB-11058, a new cephalosporin with high penicillin-binding protein 2a affinity and activity in experimental endocarditis due to homogeneously methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. (2004) 48:4322-4327.
   PubMed Web of Science ®Google Scholar
• SPRINGER DM, LUH BY, BRONSON JJ: Anti-MRSA cephems. Part 1: C-3 substituted thiopyridinium derivatives. Bioorganic Med Chem. Lett. (2001) 11:797-801.
   PubMed Web of Science ®Google Scholar
• SPRINGER DM, LUH BY, GOODRICH JT, BRONSON JJ: Anti-MRSA cephems. Part 3: additional C-7 acid derivatives. Bioorganic Med. Chem. (2003) 11:281-291.
   PubMed Web of Science ®Google Scholar
• SPRINGER DM, LUH BY, GOODRICH J, BRONSON JJ: Anti-MRSA cephems. Part 2: C-7 cinnamic acid derivatives. Bioorganic Med. Chem. (2003) 11:265-279.
   PubMed Web of Science ®Google Scholar
• ISHIKAWA T, NAKAYAMA Y, TOMIMOTO M et al.: Studies on anti-MRSA parenteral cephalosporins. IV. A novel water-soluble N-phosphono type prodrug for parental administration. J. Antibiotics (2001) 54:364-374.
   PubMed Web of Science ®Google Scholar
• HANAKI H, NOMURA S, AKAGI H, HIRAMATSU K: Improvement of water-soluble cephalosporin derivatives having antibacterial activity against methicillin-resistant Staphylococcus aureus. Chemotherapy (2001) 47:170-176.
   PubMed Web of Science ®Google Scholar
• CLARK J, FUNG-TOMC JC, MINASSIAN B et al.: In vitro and in vivo activities of a novel cephalosporin, BMS-247243, against organisms other than staphylococci. Antimicrob. Agents Chemother. (2002) 46:1108-1111.
   PubMed Web of Science ®Google Scholar
• IDA T, TSUSHIMA M, ISHII T, ATSUMI K, TAMURAA: CP-6679, a new injectable cephalosporin with broad spectrum and potent activities against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. J. Infect. Chemother. (2002) 8:138-144.
   PubMed Web of Science ®Google Scholar
• YOSHIZAWA H, ITANI H, ISHIKURA K et al.: S-3578, a new broad spectrum parenteral cephalosporin exhibiting potent activity against both methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Synthesis and structure–activity relationships. J. Antibiotics (2002) 55:975-992.
   PubMed Web of Science ®Google Scholar
• MALOUIN F, BLAIS J, CHAMBERLAND S et al.: RWJ-54428 (MC-02,479), a new cephalosporin with high affinity for penicillin-binding proteins, including PBP2′a, and stability to staphylococcal β-lactamases. Antimicrob. Agents Chemother. (2003) 47:658-664.
   PubMed Web of Science ®Google Scholar
• HUANG V, BROWN WJ, RYBAK MJ: In vitro activities of a novel cephalosporin, CB-181963 (CAB-175), against methicillin-susceptible or -resistant Staphylococcus aureus and glycopeptide-intermediate susceptible staphylococci. Antimicrob. Agents Chemother. (2004) 48:2719-2723.
   PubMed Web of Science ®Google Scholar
• PAGE MG: Cephalosporins in clinical development. Expert Opin. Investig. Drugs (2004) 13:973-985.
   PubMed Web of Science ®Google Scholar
• PAGE MG: Anti-MRSA β-lactams in clinical development. Curr. Opin. Pharmacol. (2006) 6:480-485.
   PubMed Web of Science ®Google Scholar
• HEBEISEN P, HEINZE-KRAUSS I, ANGEHRN P, HOHL P, PAGE MG, THEN RL: In vitro and in vivo properties of RO 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. (2001) 45:825-836.
   PubMed Web of Science ®Google Scholar
• HECKER SJ, CALKINS T, PRICE ME et al.: Prodrugs of cephalosporin RWJ-333441 (MC-04,546) with improved aqueous solubility. Antimicrob. Agents Chemother. (2003) 47:2043-2046.
   PubMed Web of Science ®Google Scholar
• ISHIKAWA T, KAMIYAMA K, NAKAYAMA Y, IIZAWA Y, OKONOGI K, MIYAKE A: Studies on anti-MRSA parenteral cephalosporins. III. Synthesis and antibacterial activity of 7-β-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2 (Z)-alkoxyiminoacetamido-3. J. Antibiotics (2001) 54:257-277.
   PubMed Web of Science ®Google Scholar
• ISHIKAWA T, MATSUNAGA NI, TAWADA H et al.: TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Bioorganic Med. Chem. (2003) 11:2427-2437.
   PubMed Web of Science ®Google Scholar
• HEBEISEN P, ANGEHRN P, HEINZE-KRAUSS I et al.: Synthesis and SAR of pyrrolidinone-3-ylidenemethyl cephems against methicillin-resistant Staph. aureus. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (1998):238 Poster F-21.
   Google Scholar
• BOGDANOVICH T, EDNIE LM, SHAPIRO S, APPELBAUM PC: Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob. Agents Chemother. (2005) 49:4210-4219.
   PubMed Web of Science ®Google Scholar
• DESHPANDE LM, JONES RN: Bactericidal activity and synergy studies of BAL-9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci. Clin. Microbiol. Infect. (2003) 9:1120-1124.
   PubMed Web of Science ®Google Scholar
• REYNOLDS D, LIVERMORE DM: Comparative activity of BAL-9141, daptomycin and linezolid versus S. aureus from bacteremias in the UK and Ireland. 44th ICAAC 2004. Poster E-2035.
   Google Scholar
• REYNOLDS R, LIVERMORE DM: Effect of culture conditions on MICs of BAL-9141, representing a new class of cephalosporins active against MRSA. 44th ICAAC 2004. Abstact E-2036.
   Google Scholar
• LOVERING A, DANEL F, PAGE MGP, STRYNADKA NJ: Mechanism of action of ceftobiprole: structural basis for anti-MRSA activity. 16th European Congress of Clinical Microbiology and Infectious Diseases, ECCMID, April 2006. Nice, France (2006):Poster P-1586.
   Google Scholar
• MIYAUCHI M, HIROTA T, FUJIMOTO K, IDE J: Studies on orally active cephalosporin esters. IV Effect of the C-3 substituent of cephalosporin on the gastrointestinal absorption in mice. Chem. Pharm. Bull. (1989) 37:3272-3276.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO H, TERASAWA T, NAKAMURA A et al.: Orally active cephalosporins. Part 3: synthesis, structure–activity relationships and oral absorption of novel C-3 heteroarylmethylthiocephalosporins. Bioorg. Med. Chem. (2001) 9:465-475.
   PubMed Web of Science ®Google Scholar
• HEBEISEN P, GROSS G, HEINZE-KRAUSS I et al.: Synthesis, physicochemical and pharmacokinetic properties of water soluble prodrugs of Ro 63-9141/000. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (1998):Poster F-26.
   Google Scholar
• DUDLEY MN, HUIE K, GRIFFITH D, GLINKA T, HECKER S, MILLER G: In vitro cleavage of RWJ-442831, a soluble prodrug of the anti-MRSA cephalosporin RWJ-54428, in serum and liver homogenates from animals and humans. 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2003):Poster F-549.
   Google Scholar
• MORI N, KODAMA T, SKAI A et al.: AS-924, a novel, orally active, bifunctional prodrug of ceftizoxime: physicochemical properties, oral absorption in animals, and antibacterial activity. Int. J. Antimicrob. Agents (2001) 18:451-461.
   PubMed Web of Science ®Google Scholar
• VAUDAUX P, GJINOVCI A, BENTO M, LI D, SCHRENZEL J, LEW DP: Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. (2005) 49:3789-3793.
   PubMed Web of Science ®Google Scholar
• CHAMBERS HF: Ceftobiprole: in vivo profile of a bactericidal cephalosporin. Clin. Microbiol. Infect. (2006) 12(Suppl. 2):17-22.
   PubMed Web of Science ®Google Scholar
• CHAMBERS HF: Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. (2005) 49:884-888.
   PubMed Web of Science ®Google Scholar
• SCHMITT-HOFFMANN A, YIN L, CALHOUN J, THOMAS J, SHAPIRO S, SPICKERMANN J: Distribution of ceftobiprole in bone matrix and bone marrow in a rabbit MRSA osteomyelitis model. 45th ICAAC 2005. Poster B-2007.
   Google Scholar
• YIN LY, CALHOUN JH, THOMAS JK, SHAPIRO S, SCHMITT-HOFFMANN AH, URWYLER H: Efficacies of ceftobiprole medocaril (BDR-M), vancomycin (VAN) and linezolid (LZD) for treatment of methicillin-resistant staphylococcus aureus (MRSA) osteomyelitis: studies with a rabbit model. 43rd IDSA 2005.
   Google Scholar
• LODISE TP, DRUSANO GL, MA, L, PYPSTRA R, KAHN J, NOEL GJ: Determination of optimal renal dosage adjustment for ceftobiprole (BPR). 43rd IDSA 2005. (527).
   Google Scholar
• SCHMITT-HOFFMANN A, ROOS B, SCHLEIMER M et al.: Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob. Agents Chemother. (2004) 48:2570-2575.
   PubMed Web of Science ®Google Scholar
• SCHMITT-HOFFMANN A, NYMAN L, ROOS B et al.: Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob. Agents Chemother. (2004) 48:2576-2578.
   PubMed Web of Science ®Google Scholar
• HEEP M, QUERNER S, HARSCH M, O’RIORDAN W: Ceftobiprole (BAL-5788), the first of a new class of anti-MRSA cephalosporins: microbiological results from a Phase II study in complicated skin and skin structure infections. 44th ICAAC 2004. Poster L-361.
   Google Scholar
• NOEL GJ, STRAUSS RS, PYPSTRA R; 00154 STUDY GROUP: Successful treatment of complicated skin infections (cSSSI) Due to staphylococci, including methicillin-resistant Staphylococcus Aureus (MRSA) with ceftobiprole. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (2006):Poster L-1212.
   Google Scholar
• BARRETT JF: Can biotech deliver new antibiotics? Curr. Opin. Microbiol. (2005) 8:498-503.
   PubMed Web of Science ®Google Scholar
• PAGE MG, WALSH CT: Antimicrobials. Curr. Opin. Microbiol. (2005) 8:495-497.
   Web of Science ®Google Scholar